

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)



(10) International Publication Number
WO 2022/038411 A1

(51) International Patent Classification:

C07K 14/725 (2006.01) C07K 14/735 (2006.01)
A61K 39/00 (2006.01) C07K 16/00 (2006.01)
C07K 14/705 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/IB2021/000556

(22) International Filing Date:

18 August 2021 (18.08.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/067,629 19 August 2020 (19.08.2020) US

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **ASTELLAS PHARMA, INC.** [JP/JP]; 5-1, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP).

(72) Inventors: **MORIYA, Ryuichi**; 5-1, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **SHIRAI, Hiroki**; 5-1, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **SOGA, Shinji**; 5-1, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **SHIMADA, Naoko**; 5-1, Nihonbashi-honcho 2-chome, Chuo-ku, Tokyo 103-8411 (JP). **RUSSELL, David, William**; 3005 1st Avenue, Seattle, WA 98121 (US).

(74) Agent: **TANAKA, Shinichiro** et al.; Nakamura & Partners, Shin-Tokyo Bldg., 3-1, Marunouchi 3-chome, Chiyoda-ku, Tokyo 100-8355 (JP).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: HUMAN NON-NATURALLY OCCURRING MODIFIED FC REGION OF IGG SPECIFICALLY BINDING TO NON-NATURALLY OCCURRING MODIFIED FC RECEPTOR

(57) Abstract: The present invention provides a polypeptide comprising a modified Fc region of an IgG, and a modified Fcγ receptor that binds specifically to the polypeptide, and methods for treating or preventing a disease or a disorder in a patient using immunotherapy.

WO 2022/038411 A1